You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
International Journal of Molecular Sciences
Download PDF
  • Editorial
  • Open Access

10 November 2025

Special Issue “Fractalkine (CX3CL1) and Its Chemoattractant and Adhesion Molecule Properties in Health and Disease”

Department of Biophysics, Physiology & Pathophysiology, Faculty of Health Sciences, Medical University of Warsaw, 02-004 Warsaw, Poland
Int. J. Mol. Sci.2025, 26(22), 10899;https://doi.org/10.3390/ijms262210899
This article belongs to the Special Issue Fractalkine (CX3CL1) and Its Chemoattractant and Adhesion Molecule Properties in Health and Disease
Version Notes
Order Reprints
The discovery of the unique chemokine CX3CL1 (fractalkine, neurotactin) in 1997 by two independent research teams led by Bazan and Pan initiated a new chapter in the understanding of inflammation and cell-to-cell communication [,,]. While other chemokines are typically soluble, fractalkine exhibits form duality, manifesting itself as a membrane-bound molecule that can also be shed into a soluble form []. Its duality of function corresponds to its form; the membrane-bound form acts as a powerful cell adhesion molecule that binds leukocytes to endothelial cells during the inflammatory response, and the soluble form, fractalkine, is a potent chemoattractant that guides leukocytes such as T cells and monocytes toward sites of inflammation [,]. This versatility continues to make it difficult for researchers to interpret research results, which sometimes indicate contradictory actions of fractalkine in various physiological and pathological processes, particularly in the brain, inflammation, and cancer [,,,].
This Special Issue, dedicated to fractalkine, aims to update and summarize the current state of knowledge regarding its importance in viral infections [,] and its involvement in the pathomechanisms of neurodegenerative diseases [,], complications of diabetes [,], cancer [], and nonobstructive coronary artery disease (NO-CAD) []. Opinions regarding these issues presented in this editorial also consider existing controversies.
Recent studies have shown that fractalkine plays an important role in regulating the host immune response to viral infection []. Changes in the expression of CX3CL1 and its sole receptor, CX3CR1, are implicated in the pathomechanisms of human immunodeficiency virus (HIV), SARS-CoV-2, influenza virus, cytomegalovirus (CMV), and respiratory syncytial virus (RSV) infections [,,,]. In the case of RSV, CX3CR1 is a coreceptor for the virus and is expressed by airway epithelial cells and diverse immune cells; this is due to the presence of a highly conserved amino acid motif (CX3C motif) in the RSV G protein that enables binding to CX3CR1 and is also present in fractalkine [,]. Altered functioning of the CX3CR1-CX3CL1 axis and, consequently, an impaired host immune response should therefore be considered during the development of an efficient vaccine and specific pharmacological treatment.
Since its discovery, fractalkine has been extensively studied in relation to the nervous system, where it is naturally highly expressed. The CX3CL1–CX3CR1 interaction plays an important role in neuron–microglia signaling and, as a crucial modulator of microglial activation, has become a target for innovative therapies for neuroinflammation and neurodegenerative diseases [,,,]. One of the rationales for such actions may be the results of recent in vitro studies, which revealed a loss of neurofilaments and spheroids in a neuron–astrocyte–microglia coculture system after the administration of cerebrospinal fluid from patients with Alzheimer’s disease. The soluble form of fractalkine may contribute to this destabilization of neurofilaments, as well as to disturbances in cellular adhesion processes and intercellular contacts []. Nevertheless, despite numerous studies regarding the involvement of CX3CL1 and CX3CR1 in the progression of various neuroinflammatory and neurodegenerative diseases, especially Alzheimer’s and Parkinson’s diseases, unambiguous interpretation of the results is often impossible because of incompatible methodologies []. Moreover, depending on the clinical context, CX3CL1-CX3CR1 signaling may have neuroprotective effects by inhibiting microglial inflammatory processes or, conversely, maintaining/intensifying inflammation and neurotoxicity [,].
Diabetes mellitus (DM) is the most common metabolic disease in humans, and its prevalence is increasing worldwide in parallel with that of obesity []. A low-grade inflammatory response is typical in patients with DM, especially type 2 DM (T2DM), and plays a significant role in its development and complications [,,]. Chemokine markers of inflammation in patients with DM associated with microvascular dysfunction include increased circulating levels of fractalkine, especially in individuals with concomitant obesity [,].
In patients with diabetic retinopathy, a typical long-term complication of diabetes, soluble fractalkine plays critical roles in retinal inflammation, angiogenesis, and neuroprotection, balancing tissue damage and repair []. Although elevated fractalkine concentrations accompany retinal inflammation, fractalkine deficiency exacerbates the severity of diabetic retinopathy. Furthermore, exogenous fractalkine has been shown to reduce inflammation, oxidative stress, and neuronal damage in states of fractalkine deficiency [,]. Preclinical evidence has therefore indicated the therapeutic potential of fractalkine, as modulating the state of microglial activation to ameliorate neovascularization may prove beneficial for managing diabetic retinopathy [,].
Another serious complication of diabetes is diabetic encephalopathy, which is characterized by cognitive impairment and motor dysfunction []. The crucial factor in this chronic neurological complication is increased pathological microglia activity, which is largely dependent on disturbed CX3CL1-CX3CR1 signaling [,]. Here, fractalkine signaling fits into the picture of the vicious cycle of disease created by microglia–neuron interactions during the course of neuroinflammation accompanying diabetic encephalopathy (Figure 1).
Figure 1. The importance of microglia and CX3CL1/CX3CR1 signaling in the vicious cycle of microglia–neuron interaction during neuroinflammation in diabetic encephalopathy. Adopted from []. Microglial activation in diabetic encephalopathy occurs as a result of the action of signaling pathways related to the following: ❶ pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), triggering receptor expressed on myeloid cells 2/DNAX-activating protein of 12 kDa (TRM2/DAP12), and advanced glycation end product/receptor for advanced glycation end product (AGE-RAGE); ❷ the activation of p38 mitogen-activated protein kinases, a class of mitogen-activated protein kinases (MAPKs), p38 MAPK, and ❸ purinergic signaling. Microglial inflammation may also develop as a consequence of blocking the interaction of the immunomodulatory protein CD200 with its receptor CD200R (marked with crossed-out red lines) ❹, because the CD200/CD200R signaling induces immunosuppression due to the inhibition of macrophages, the induction of regulatory T cells, the switching of cytokine profiles from T helper-1 (Th1) to T helper-2 (Th2), the inhibition of tumor-specific T-cell immunity, and the induction of myeloid-derived suppressor cells (MDSCs) []. Neuronal hyperactivity in diabetic encephalopathy may be caused by both neurotoxic factors outside microglia and an inflammatory response within microglia. Neurotoxic agents increase the risk of cognitive deficits due to impaired synaptic plasticity. Whatever the cause, neuronal hyperactivity has a feedback-activating effect on microglia by releasing slow-acting microglial activators, such as matrix metalloproteinase-9 (MMP-9), adenosine triphosphate (ATP), monocyte chemoattractant protein-1 (MCP-1), and fractalkine (CX3CL1) ❺. The soluble form of CX3CL1 (sCX3CL1) has a proinflammatory effect by stimulating metabotropic CX3CR1 receptors expressed in microglial cells ❻.
Taking the above into account, the goal of therapeutic management in patients with diabetic encephalopathy should be, in addition to optimal glycemic control, the promotion of neuroprotective effects or the inhibition of the neurotoxic effects of the CX3CL1-CX3CR1 signaling axis [].
The role of fractalkine in cancer progression and its related potential in antineoplastic therapy remain unclear, especially given the presence of two forms of this chemokine. The chemoattractant properties of fractalkine can limit tumor growth by increasing the infiltration of immune cells, including T cells, natural killer cells, and activated dendritic cells [,,]. However, studies have demonstrated that tumorigenesis with enhanced metastasis and invasion requires increased tumor expression of fractalkine or its receptor [,,]. These discrepancies regarding the prognostic significance of CX3CL1-CX3CR1 axis activity in different cancers may indicate that the role of fractalkine in tumor biology cannot be limited to interactions with its cognate receptor []. Fractalkine interactions with only CX3CR1 may not cover the full spectrum of its pro- or antitumor immunoactivity [].
Nonobstructive coronary artery disease (NO-CAD) is a heterogeneous group of conditions characterized by less than 50% narrowing in at least one major coronary artery with a fractional flow reserve (FFR) of ≤0.80, as observed by coronary angiography []. The results of recent studies indicate that fractalkine signaling may be an important factor in the pathogenesis and progression of NO-CAD, whose proinflammatory, proatherosclerotic, and microvascular-dysfunction-causing effects are well documented [,]. Moreover, promising preliminary results have shown that administering the CX3CR1 antagonist KAND567 to patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) can prevent hyperinflammation, an adverse reaction of the immune system [,]. However, further research is needed to determine why the number of CX3CR1-expressing circulating effector T cells decreases substantially after reperfusion only in some patients [].

Conflicts of Interest

The author declares no conflict of interest.

References

  1. Bazan, J.F.; Bacon, K.B.; Hardiman, G.; Wang, W.; Soo, K.; Rossi, D.; Greaves, D.R.; Zlotnik, A.; Schall, T.J. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385, 640–644. [Google Scholar] [CrossRef]
  2. Pan, Y.; Lloyd, C.; Zhou, H.; Dolich, S.; Deeds, J.; Gonzalo, J.A.; Vath, J.; Gosselin, M.; Ma, J.; Dussault, B.; et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997, 387, 611–617, Erratum in Nature 1997, 389, 100. [Google Scholar] [CrossRef]
  3. Tanaka, Y.; Hoshino-Negishi, K.; Kuboi, Y.; Tago, F.; Yasuda, N.; Imai, T. Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases. Immunotargets Ther. 2020, 9, 241–253. [Google Scholar] [CrossRef]
  4. Poniatowski, Ł.A.; Wojdasiewicz, P.; Krawczyk, M.; Szukiewicz, D.; Gasik, R.; Kubaszewski, Ł.; Kurkowska-Jastrzębska, I. Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents. Mol. Neurobiol. 2017, 54, 2167–2188. [Google Scholar] [CrossRef]
  5. Foussat, A.; Coulomb-L’Hermine, A.; Gosling, J.; Krzysiek, R.; Durand-Gasselin, I.; Schall, T.; Balian, A.; Richard, Y.; Galanaud, P.; Emilie, D. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur. J. Immunol. 2000, 30, 87–97. [Google Scholar] [CrossRef]
  6. Szukiewicz, D. CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis. Int. J. Mol. Sci. 2024, 25, 4679. [Google Scholar] [CrossRef]
  7. Frias-Anaya, E.; Gallego-Gutierrez, H.; Gongol, B.; Weinsheimer, S.; Lai, C.C.; Orecchioni, M.; Sriram, A.; Bui, C.M.; Nelsen, B.; Hale, P.; et al. Mild Hypoxia Accelerates Cerebral Cavernous Malformation Disease Through CX3CR1-CX3CL1 Signaling. Arterioscler. Thromb. Vasc. Biol. 2024, 44, 1246–1264. [Google Scholar] [CrossRef]
  8. Wojdasiewicz, P.; Poniatowski, L.A.; Kotela, A.; Deszczyński, J.; Kotela, I.; Szukiewicz, D. The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: Occurrence and potential role in osteoarthritis. Arch. Immunol. Ther. Exp. 2014, 62, 395–403. [Google Scholar] [CrossRef] [PubMed]
  9. Conroy, M.J.; Lysaght, J. CX3CL1 Signaling in the Tumor Microenvironment. Adv. Exp. Med. Biol. 2020, 1231, 1–12. [Google Scholar] [CrossRef] [PubMed]
  10. Lu, X. Structure and Function of Ligand CX3CL1 and its Receptor CX3CR1 in Cancer. Curr. Med. Chem. 2022, 29, 6228–6246. [Google Scholar] [CrossRef] [PubMed]
  11. Zhang, C.; Zhang, Y.; Zhuang, R.; Yang, K.; Chen, L.; Jin, B.; Ma, Y.; Zhang, Y.; Tang, K. Alterations in CX3CL1 Levels and Its Role in Viral Pathogenesis. Int. J. Mol. Sci. 2024, 25, 4451. [Google Scholar] [CrossRef]
  12. Rivas-Fuentes, S.; Salgado-Aguayo, A.; Santos-Mendoza, T.; Sevilla-Reyes, E. The Role of the CX3CR1-CX3CL1 Axis in Respiratory Syncytial Virus Infection and the Triggered Immune Response. Int. J. Mol. Sci. 2024, 25, 9800. [Google Scholar] [CrossRef]
  13. Gutiérrez, I.L.; Martín-Hernández, D.; MacDowell, K.S.; García-Bueno, B.; Caso, J.R.; Leza, J.C.; Madrigal, J.L.M. CX3CL1 Regulation of Gliosis in Neuroinflammatory and Neuroprotective Processes. Int. J. Mol. Sci. 2025, 26, 959. [Google Scholar] [CrossRef] [PubMed]
  14. Merino, J.J.; Muñetón-Gómez, V.; Alvárez, M.I.; Toledano-Díaz, A. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer’s Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD? Curr. Alzheimer Res. 2016, 13, 403–412. [Google Scholar] [CrossRef] [PubMed]
  15. Sheng, X.; Zhang, C.; Zhao, J.; Xu, J.; Zhang, P.; Ding, Q.; Zhang, J. Microvascular destabilization and intricated network of the cytokines in diabetic retinopathy: From the perspective of cellular and molecular components. Cell Biosci. 2024, 14, 85. [Google Scholar] [CrossRef]
  16. Wątroba, M.; Grabowska, A.D.; Szukiewicz, D. Chemokine CX3CL1 (Fractalkine) Signaling and Diabetic Encephalopathy. Int. J. Mol. Sci. 2024, 25, 7527. [Google Scholar] [CrossRef]
  17. Stangret, A.; Sadowski, K.A.; Jabłoński, K.; Kochman, J.; Opolski, G.; Grabowski, M.; Tomaniak, M. Chemokine Fractalkine and Non-Obstructive Coronary Artery Disease-Is There a Link? Int. J. Mol. Sci. 2024, 25, 3885. [Google Scholar] [CrossRef]
  18. Sénécal, V.; Barat, C.; Gagnon, M.T.; Vanasse, F.; Leboeuf, M.; Gosselin, D.; Tremblay, M.J. Altered expression of fractalkine in HIV-1-infected astrocytes and consequences for the virus-related neurotoxicity. J. Neurovirol. 2021, 27, 279–301. [Google Scholar] [CrossRef] [PubMed]
  19. Anderson, C.S.; Chirkova, T.; Slaunwhite, C.G.; Qiu, X.; Walsh, E.E.; Anderson, L.J.; Mariani, T.J. CX3CR1 Engagement by Respiratory Syncytial Virus Leads to Induction of Nucleolin and Dysregulation of Cilia-related Genes. J. Virol. 2021, 95, e00095-21. [Google Scholar] [CrossRef]
  20. Meineke, R.; Agac, A.; Knittler, M.C.; Ludlow, M.; Osterhaus, A.D.M.E.; Rimmelzwaan, G.F. Respiratory syncytial virus glycoprotein G impedes CX3CR1-activation by CX3CL1 and monocyte function. Npj Viruses 2024, 2, 63. [Google Scholar] [CrossRef]
  21. Gao, C.; Jiang, J.; Tan, Y.; Chen, S. Microglia in neurodegenerative diseases: Mechanism and potential therapeutic targets. Signal. Transduct. Target. Ther. 2023, 8, 359. [Google Scholar] [CrossRef]
  22. Chen, P.; Zhao, W.; Guo, Y.; Xu, J.; Yin, M. CX3CL1/CX3CR1 in Alzheimer’s Disease: A Target for Neuroprotection. BioMed Res. Int. 2016, 2016, 8090918. [Google Scholar] [CrossRef]
  23. Subbarayan, M.S.; Joly-Amado, A.; Bickford, P.C.; Nash, K.R. CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. Pharmacol. Ther. 2022, 231, 107989. [Google Scholar] [CrossRef]
  24. Kawamura, N.; Katsuura, G.; Yamada-Goto, N.; Nakama, R.; Kambe, Y.; Miyata, A.; Furuyashiki, T.; Narumiya, S.; Ogawa, Y.; Inui, A. Brain fractalkine-CX3CR1 signalling is anti-obesity system as anorexigenic and anti-inflammatory actions in diet-induced obese mice. Sci. Rep. 2022, 12, 12604. [Google Scholar] [CrossRef] [PubMed]
  25. Zimmet, P.Z. Diabetes and its drivers: The largest epidemic in human history? Clin. Diabetes Endocrinol. 2017, 3, 1. [Google Scholar] [CrossRef] [PubMed]
  26. Zatterale, F.; Longo, M.; Naderi, J.; Raciti, G.A.; Desiderio, A.; Miele, C.; Beguinot, F. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front. Physiol. 2020, 10, 1607. [Google Scholar] [CrossRef]
  27. Szukiewicz, D. Molecular Mechanisms for the Vicious Cycle between Insulin Resistance and the Inflammatory Response in Obesity. Int. J. Mol. Sci. 2023, 24, 9818. [Google Scholar] [CrossRef] [PubMed]
  28. Zhang, C.Y.; Liu, S.; Yang, M. Macrophage and inflammation in diabetes and metabolic dysfunction-associated steatotic liver disease: From mechanisms to therapeutic strategies. World J. Diabetes 2025, 16, 110515. [Google Scholar] [CrossRef]
  29. Sindhu, S.; Akhter, N.; Arefanian, H.; Al-Roub, A.A.; Ali, S.; Wilson, A.; Al-Hubail, A.; Al-Beloushi, S.; Al-Zanki, S.; Ahmad, R. Increased circulatory levels of fractalkine (CX3CL1) are associated with inflammatory chemokines and cytokines in individuals with type-2 diabetes. J. Diabetes Metab. Disord. 2017, 16, 15. [Google Scholar] [CrossRef]
  30. Schinzari, F.; Tesauro, M.; Campia, U.; Cardillo, C. Increased fractalkine and vascular dysfunction in obesity and in type 2 diabetes. Effects of oral antidiabetic treatment. Vascul. Pharmacol. 2020, 128–129, 106676. [Google Scholar] [CrossRef]
  31. Cardona, S.M.; Mendiola, A.S.; Yang, Y.C.; Adkins, S.L.; Torres, V.; Cardona, A.E. Disruption of Fractalkine Signaling Leads to Microglial Activation and Neuronal Damage in the Diabetic Retina. ASN Neuro 2015, 7, 1759091415608204. [Google Scholar] [CrossRef] [PubMed]
  32. Mills, S.A.; Jobling, A.I.; Dixon, M.A.; Bui, B.V.; Vessey, K.A.; Phipps, J.A.; Greferath, U.; Venables, G.; Wong, V.H.Y.; Wong, C.H.Y.; et al. Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic retinopathy. Proc. Natl. Acad. Sci. USA 2021, 118, e2112561118. [Google Scholar] [CrossRef] [PubMed]
  33. Hu, A.; Schmidt, M.H.H.; Heinig, N. Microglia in retinal angiogenesis and diabetic retinopathy. Angiogenesis 2024, 27, 311–331. [Google Scholar] [CrossRef]
  34. Mazumdar, D.; Singh, S. Understanding diabetic encephalopathy: A model-based approach to explore cognitive and motor impairments through glutamatergic dysregulation. Mol. Biol. Rep. 2025, 52, 945. [Google Scholar] [CrossRef]
  35. Liu, Y.; Li, M.; Zhang, Z.; Ye, Y.; Zhou, J. Role of microglia-neuron interactions in diabetic encephalopathy. Ageing Res. Rev. 2018, 42, 28–39. [Google Scholar] [CrossRef]
  36. Rütsche, D.; Michalak-Micka, K.; Zielinska, D.; Moll, H.; Moehrlen, U.; Biedermann, T.; Klar, A.S. The Role of CD200-CD200 Receptor in Human Blood and Lymphatic Endothelial Cells in the Regulation of Skin Tissue Inflammation. Cells 2022, 11, 1055. [Google Scholar] [CrossRef] [PubMed]
  37. Zhuang, Q.; Cheng, K.; Ming, Y. CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe? Curr. Gene Ther. 2017, 17, 442–452. [Google Scholar] [CrossRef]
  38. Stangret, A.; Dykacz, W.; Jabłoński, K.; Wesołowska, A.; Klimczak-Tomaniak, D.; Kochman, J.; Tomaniak, M. The cytokine trio—Visfatin, placental growth factor and fractalkine—And their role in myocardial infarction with non-obstructive coronary arteries (MINOCA). Cytokine Growth Factor Rev. 2023, 74, 76–85. [Google Scholar] [CrossRef]
  39. Ekinci, Y.; Richardson, G.; Spyridopoulos, I. A Phase IIa Clinical Trial of KAND567, Fractalkine Receptor Inhibitor, in Patients with ST-Elevation Acute Myocardial Infarction after Percutaneous Coronary Intervention. J. Pharmacol. Exp. Ther. 2024, 389 (Suppl. 3), 472–473. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Download PDF
β-Sitosterol Enhances the Anticancer Efficacy of Oxaliplatin in COLO-205 Cells via Apoptosis and Suppression of VEGF-A, NF-κB-p65, and β-Catenin
Previous
The Role of IL-17 in Periodontitis and Its Systemic Connections
Next